Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives
Bliumenberg, A.G.; Gorbacheva, L.B.; Gorbunova, V.A.; Kozachenko, V.P.; Lankin, V.Z.
Biulleten' Eksperimental'noi Biologii i Meditsiny 122(12): 651-654
1996
ISSN/ISBN: 0365-9615 PMID: 9280465 Document Number: 463392
Document emailed within 1 workday
Related Documents
Neubauer, H.; Stefanova, M.; Solomayer, E.; Meisner, C.; Zwirner, M.; Wallwiener, D.; Fehm, T. 2008: Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer Anticancer Research 28(2a): 949-955Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Johnson, S.W.; Laub, P.B.; Beesley, J.S.; Ozols, R.F.; Hamilton, T.C. 1997: Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines Cancer Research 57(5): 850-856
Mandic, A.; Vujkov, T.; Malbasa, Z. 2003: Paclitaxel or docetaxel combined with platinum in advanced ovarian cancer? Journal of BUON: Official Journal of the Balkan Union of Oncology 8(1): 19-22
Welch, R.S.; James, R.D.; Wilkinson, P.M.; Belli, F.; Cowan, R.A. 1995: Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer Cancer Journal from Scientific American 1(4): 261-266
Vogl, S.E.; Pagano, M.; Kaplan, B.H.; Einhorn, N.; Arseneau, J.; Moukhtar, M.; Greenwald, E. 1980: Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapy Obstetrics and Gynecology 56(5): 635-640
Kocic, M.; Nikolic, S.; Zegarac, M.; Djurisic, I.; Soldatovic, I.; Milenkovic, P.; Kocic, J. 2016: Prognostic factors and outcomes of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer - A single tertiary institution experience Journal of BUON: Official Journal of the Balkan Union of Oncology 21(5): 1176-1183
Scarfone, G.; Villa, A.; Parazzini, F.; Sciatta, C.; Polverino, G.; Bolis, G. 1999: A phase I-II trial of high-dose ifosfamide in patients with ovarian cancer refractory or resistant to platinum and/or paclitaxel-containing chemotherapy Tumori 85(4): 217-219
Hong, R.; Ma, F.; Shi, X.; Li, Q.; Zhang, P.; Yuan, P.; Wang, J.; Fan, Y.; Cai, R.; Li, Q.; Xu, B. 2014: Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs Zhonghua Zhong Liu Za Zhi 36(10): 788-792
Tropé, C.; Kristensen, G.; Kisic, J.; Kaern, J. 2001: Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer European Journal of Gynaecological Oncology 22(3): 223-227
Tanaka, H.; Umekawa, T.; Nagao, K.; Ishihara, A.; Toyoda, N. 2003: Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports European Journal of Gynaecological Oncology 24(3-4): 337-340
Linasmita, V.; Wilailak, S.; Srisupundit, S.; Tangtrakul, S.; Bullangpoti, S.; Israngura, N. 1998: Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital Journal of the Medical Association of Thailand 81(1): 10-16
Shershah, S. 1985: Treatment by combined chemotherapy for recurrent ovarian cancer JPMA. Journal of the Pakistan Medical Association 35(11): 341-343
Gorbunova, V.A.; Perevodchikova, N.I.; Kozachenko, V.P.; Ryzhakov, V.M.; Marenich, A.F.; Zhordania, K.I. 1991: The potentials of combined chemotherapy in disseminated ovarian cancer Akusherstvo i Ginekologiia 2: 54-57
Nishikawa, A.; Hashimoto, H.; Takeda, M.; Kontani, K.; Miyatake, T.; Mimura, M.; Nagamatsu, M.; Yokoi, T. 2016: Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy European Journal of Gynaecological Oncology 37(4): 451-454
Sugimori, H.; Kidera, Y.; Matsuyama, T. 1982: Combined chemotherapy of ovarian cancer with special reference to carboquone Gan to Kagaku Ryoho. Cancer and ChemoTherapy 9(1): 66-71
Inagaki, J.; Ogawa, M.; Horikoshi, N.; Ezaki, K.; Inoue, K.; Aiba, K.; Komyo, M.; Miyamoto, H.; Ikeda, K.; Kubo, H. 1983: Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation Gan no Rinsho. Japan Journal of Cancer Clinics 29(10): 1291-1295
Webb, M.J.; Malkasian, G.D.; Jorgensen, E.O. 1974: Factors influencing ovarian cancer survival after chemotherapy Obstetrics and Gynecology 44(4): 564-570
Scotto, V.; Sbiroli, C. 1991: Weekly cis-platinum as third line chemotherapy in advanced ovarian carcinoma. Phase Ii study European Journal of Gynaecological Oncology 12(1): 51-53
Maneechawakajorn, J.; Suksuperm, J. 2014: Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen Journal of the Medical Association of Thailand 97(Suppl 11): S69-S75